centchroman has been researched along with Cancer of Pancreas in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Behrman, SW; Chauhan, N; Chauhan, SC; Ebeling, MC; Ganju, A; Gara, RK; Jaggi, M; Khan, S; Singh, MM; Thompson, PA; Yallapu, MM; Zafar, N; Zhao, H | 1 |
| Balabathula, P; Balakrishna, S; Behrman, SW; Chauhan, N; Chauhan, SC; Ebeling, MC; Ellis, RT; Halaweish, FT; Jaggi, M; Khan, S; Singh, MM; Thompson, PA; Yallapu, MM; Zafar, N | 1 |
2 other study(ies) available for centchroman and Cancer of Pancreas
| Article | Year |
|---|---|
Ormeloxifene suppresses desmoplasia and enhances sensitivity of gemcitabine in pancreatic cancer.
Topics: Adenocarcinoma; Animals; Apoptosis; Benzopyrans; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Gemcitabine; Humans; Mice; Pancreatic Neoplasms; Xenograft Model Antitumor Assays | 2015 |
Nanoparticle formulation of ormeloxifene for pancreatic cancer.
Topics: Animals; Benzopyrans; Cell Line, Tumor; Cell Proliferation; Drug Carriers; Female; Humans; Lactic Acid; Mice; Mice, Nude; Nanoparticles; Pancreatic Neoplasms; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Xenograft Model Antitumor Assays | 2015 |